glp-1 drugs semaglutide GLP-1s GLP-1 Medications for Weight Loss

Key Highlights Orforglipron (Eli Lilly) * 13.6% weight loss in Phase 2 * 2.1% HbA1c reduction * Highest efficacy among the three molecules in Phase 2 * Subsequently confirmed efficacy in Phase 3 with up to 14.7% weight loss * First and only FDA-approved oral small-molecule GLP-1 receptor agonist (Foundayo) Elecoglipron (AstraZeneca) * 11.8% weight loss * 1.9% HbA1c reduction * Strong Phase 2b results * Currently advancing into a global Phase 3 program Aleniglipron (Structure Therapeutics) * 12.1% weight loss * 1.5% HbA1c reduction * Encouraging efficacy with ongoing Phase 3 development Phase 2 Efficacy Comparison Weight Loss * Orforglipron: 13.6% * Aleniglipron: 12.1% * Elecoglipron: 11.8% HbA1c Reduction * Orforglipron: 2.1% * Elecoglipron: 1.9% * Aleniglipron: 1.5% As Structure Therapeutics expanded their testing into the ACCESS II trial and evaluated higher doses (specifically escalation protocols reaching 180 mg and 240 mg), the efficacy numbers jumped significantly

J Clin Invest 1933;12:1083-1090

Studies highlight that patients following their script experience significant weight losscomparable to surgical interventions

However, it's important to monitor for mood changes during treatment, as depression and suicidal ideation have been reported with semaglutide and require medical attention

Lillys growth is still volume-led, but lower realized prices are already visible in both U.S

Medical weight loss in Salt Lake City at Rise Rejuvenation Center is a physician-supervised protocol utilizing FDA-approved medications like Semaglutide and Tirzepatide to regulate metabolic health